Background: Diabetic foot ulcers (DFUs) are a severe complication of diabetes mellitus, affecting 15-25% of diabetic patients during their lifetime. DFUs result from peripheral neuropathy and peripheral arterial disease, leading to chronic wounds with a high risk of infection, gangrene, and lower extremity amputations. Standard treatment includes blood glucose control, wound care, and offloading, while advanced therapies such as Epidermal Growth Factor (EGF) dressings have emerged as promising alternatives. Materials & Methods: A randomized study was conducted to compare the effectiveness of EGF dressings versus conventional dressings in DFU management. Patients were assessed based on ulcer size reduction, granulation tissue formation, rate of healing, pain levels, and need for secondary surgical interventions. Follow-ups were conducted at 1 week, 1 month, and 6 months to analyze wound healing outcomes. Results: Patients receiving EGF dressings demonstrated significantly faster wound healing compared to those treated with conventional dressings. The rate of ulcer surface area reduction was significantly higher in the EGF group (66.59 ± 10.46%) compared to the conventional group (48.00 ± 15.88%, p < 0.001). Granulation tissue formation was also superior in the EGF group (65.80 ± 16.96% vs. 38.43 ± 27.74%, p < 0.001). A lower percentage of patients in the EGF group had ulcer discharge (3.12% vs. 62.5% in the conventional group). However, the EGF group required more frequent secondary suturing interventions in the initial stages. Conclusion: EGF dressings significantly enhance wound healing in DFUs by accelerating ulcer closure, promoting granulation tissue formation, and reducing discharge rates. While requiring more frequent early interventions, EGF therapy ultimately results in better long-term outcomes, reducing the risk of complications and hospitalizations. These findings support the integration of EGF into standard DFU treatment protocols.